{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:11:31Z","timestamp":1790964691405,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,11,19]],"date-time":"2014-11-19T00:00:00Z","timestamp":1416355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Novartis Pharma AG"},{"name":"Novartis Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2015,2]]},"abstract":"<jats:p>Long\u2010term controlled studies are needed to inform on the clinical benefit of chelation therapy for myocardial iron removal in transfusion\u2010dependent beta thalassemia patients. In a 1\u2010year nonrandomized extension to the CORDELIA study, data collected from patients with myocardial siderosis provided additional information on deferasirox or deferoxamine (DFO) efficacy and safety. Myocardial (m)T2* increased from baseline 11.6 to 15.9 ms in patients receiving deferasirox for 24 months (<jats:italic>n<\/jats:italic> = 74; geometric mean [<jats:italic>G<\/jats:italic><jats:sub>mean<\/jats:sub>] ratio of month 24\/baseline 1.38 [95% confidence interval 1.28, 1.49]) and from 10.8 to 14.2 ms in those receiving DFO (<jats:italic>n<\/jats:italic> = 29; <jats:italic>G<\/jats:italic><jats:sub>mean<\/jats:sub> ratio 1.33 [1.13, 1.55]; <jats:italic>P<\/jats:italic> = 0.93 between groups). Improved mT2* with deferasirox was evident across all subgroups evaluated irrespective of baseline myocardial (mT2* &lt; 10 vs. \u2265 10 ms) or liver (LIC &lt;15 vs. \u226515 mg Fe\/g dw) iron burden. Mean LVEF was stable and remained within normal limits with deferasirox or DFO. Liver iron concentration decreased from high baseline values of 30.6 \u00b1 18.0 to 14.4 \u00b1 16.6 mg Fe\/g dw at month 24 in deferasirox patients and from 36.8 \u00b1 15.6 to 11.0 \u00b1 12.1 mg Fe\/g dw in DFO patients. The long\u2010term safety profile of deferasirox or DFO was consistent with previous reports; serious drug\u2010related AEs were reported in 6.8% of deferasirox and 6.9% of DFO patients. Continued treatment of severely iron\u2010overloaded beta thalassemia patients with deferasirox or DFO led to sustained improvements in myocardial iron irrespective of high or low baseline myocardial or liver iron burden, in parallel with substantial improvements in liver iron (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/Clinicaltrials.gov\">Clinicaltrials.gov<\/jats:ext-link> identifier: NCT00600938). Am. J. Hematol. 90:91\u201396, 2015. \u00a9 2014 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23876","type":"journal-article","created":{"date-parts":[[2014,10,27]],"date-time":"2014-10-27T02:57:53Z","timestamp":1414378673000},"page":"91-96","source":"Crossref","is-referenced-by-count":50,"title":["Sustained improvements in myocardial T2* over 2 years in severely iron\u2010overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine"],"prefix":"10.1002","volume":"90","author":[{"given":"Dudley J.","family":"Pennell","sequence":"first","affiliation":[{"name":"NIHR Cardiovascular Biomedical Research Unit Royal Brompton Hospital London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Porter","sequence":"additional","affiliation":[{"name":"Department of Haematology University College London London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Piga","sequence":"additional","affiliation":[{"name":"Department of Paediatrics University of Turin Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong\u2010Rong","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Guangxi Medical University Nanning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"El\u2010Beshlawy","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology Cairo University Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Elalfy","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Ain Shams University Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akif","family":"Yesilipek","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\u2010Oncology Akdeniz University Antalya Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurdanur","family":"Kilin\u00e7","sequence":"additional","affiliation":[{"name":"Department of Biochemistry Cukurova University Medical Facility Adana Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dany","family":"Habr","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled M.","family":"Musallam","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwu","family":"Shen","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesim","family":"Aydinok","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology Ege University Hospital Izmir Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the CORDELIA study investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,11,19]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"1187","article-title":"Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine","volume":"89","author":"Borgna\u2010Pignatti C","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02357-6"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.03.083"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.013193"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-148767"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2001.2822"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.049957"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-497842"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2948"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.648790"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00587.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1532-429X-10-12"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-250308"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-009-0838-z"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21830"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.007641"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31829b2be6"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.031468"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05202.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.874487"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.06.065"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409013310903"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.3.739"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.1.17"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409013310902"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-217455"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-316646"},{"key":"e_1_2_6_29_1","unstructured":"Thalassaemia International Federation.Guidelines for the clinical management of thalassaemia 2nd Revised Edition.2008. Available at:http:\/\/www.thalassaemia.org.cy\/wp-content\/uploads\/pdf\/educational-programmes\/Publications\/Guidelines%20%282008%29\/Thalassaemia%20Guidelines%20ENGLISH.pdf."}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23876","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23876","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.23876","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T05:13:30Z","timestamp":1696569210000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,19]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1002\/ajh.23876"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23876","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,19]]}}}